Veliparib
Malignant Adrenal Gland Pheochromocytoma
Explore 1 assets in Malignant Adrenal Gland Pheochromocytoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Vanderbilt-Ingram Cancer Center
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02831179CT.gov Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Adrenal Gland Pheochromocytoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Veliparib (this asset) | Vanderbilt-Ingram Cancer Center | P1 | CC · 43 |
| Pembrolizumab | M.D. Anderson Cancer Center | P2 | CCC |
| Oxodotreotide | M.D. Anderson Cancer Center | P2 | CCC |
| Capecitabine | Vanderbilt-Ingram Cancer Center | P1 | CC |
Other indications for Veliparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BBB · 74 |
| Small Cell Lung Carcinoma | — | P2 | BB · 71 |
| Triple-Negative Breast Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Veliparib in Malignant Adrenal Gland Pheochromocytoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/veliparib-malignant-adrenal-gland-pheochromocytoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →